Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005014/en/

VueLife® “HP” Series Bag cell culture testing in Saint-Gobain Life Sciences Laboratory. (Photo: Business Wire)

T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients.

Building upon the VueLife^® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife^® “HP” (high permeability) incorporates an innovative, patented laminate film layer that allows increased CO₂ and O₂ exchange versus other monolayer bag designs, yet maintains the scalability and process flexibility offered by a closed bag system. The increased permeability associated with the “HP” laminate layer was specifically designed for culturing cells requiring higher rates of respiration, such as T cells.

“The development of this product was in direct response to the market need for a cost effective culture vessel that provides efficient cell expansion in a scalable, closed system,” said Benjamin Le Quere, General Manager for the Saint-Gobain Life Sciences Bioprocess Solutions business unit. “VueLife^® “HP” is an exciting result of the marrying of our expertise in material science with our knowledge in cell culture.”

The entire family of VueLife^® cell culture bags utilize a common FEP fluid-contact layer. FEP creates an ideal environment for cell growth due to its gas permeability and liquid impermeability, while being biologically and chemically inert.

ABOUT SAINT-GOBAIN LIFE SCIENCES

Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery.

Along with material science expertise and collaborative design services, our focus on global quality and regulatory affairs allow us to be the trusted partner to organizations reaching every part of the globe. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world. Saint-Gobain Life Sciences is part of Compagnie de Saint-Gobain.

Compagnie de Saint-Gobain designs, manufactures and distributes materials and solutions which are key ingredients in the wellbeing of each of us and the future of all. They can be found everywhere in our living places and our daily life: in buildings, transportation, infrastructure and in many industrial applications. They provide comfort, performance and safety while addressing the challenges of sustainable construction, resource efficiency and climate change. Saint-Gobain operates in 70 countries with more than 180,000 employees worldwide. The Company had €42.6 billion in sales in 2019.

www.celltherapy.saint-gobain.com/products/cell-culture-processing-bags/vuelife-hp-series

View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005014/en/